Synthesis and purification of potential antimicrobial peptides by Snyder, Christopher Ryan
Eastern Michigan University
DigitalCommons@EMU
Master's Theses and Doctoral Dissertations Master's Theses, and Doctoral Dissertations, andGraduate Capstone Projects
2012
Synthesis and purification of potential
antimicrobial peptides
Christopher Ryan Snyder
Follow this and additional works at: http://commons.emich.edu/theses
Part of the Chemistry Commons
This Open Access Thesis is brought to you for free and open access by the Master's Theses, and Doctoral Dissertations, and Graduate Capstone Projects
at DigitalCommons@EMU. It has been accepted for inclusion in Master's Theses and Doctoral Dissertations by an authorized administrator of
DigitalCommons@EMU. For more information, please contact lib-ir@emich.edu.
Recommended Citation
Snyder, Christopher Ryan, "Synthesis and purification of potential antimicrobial peptides" (2012). Master's Theses and Doctoral
Dissertations. 392.
http://commons.emich.edu/theses/392
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Synthesis and Purification of Potential Antimicrobial Peptides 
 
By 
 
Christopher Ryan Snyder 
 
Thesis 
 
 
Submitted to the Department of Chemistry 
Eastern Michigan University 
in partial fulfillment of the requirements 
for the degree of 
 
MASTER OF SCIENCE 
in 
Chemistry 
 
 
Deborah Heyl-Clegg, PhD, Chair 
 
 
March 15, 2012 
Ypsilanti, Michigan 
ii 
 
THESIS APPROVAL FORM 
 
Synthesis and Purification of Potential Antimicrobial Peptides 
By 
Christopher Ryan Snyder 
APPROVED: 
 
__________________________                  ____________ 
Director: Dr. Deborah Heyl-Clegg, PhD             Date 
Thesis Chair 
 
__________________________                  ____________ 
Dr. Timothy Brewer, PhD                                         Date 
Committee Member 
 
__________________________                  ____________ 
Dr. Jamie Scaglione, PhD                 Date 
Committee Member 
 
__________________________                  ____________ 
Dr. Ross Nord, PhD                Date 
Department Head 
 
__________________________                  ____________ 
Dr. Deborah de Laski-Smith, PhD              Date 
Interim Dean of the Graduate School 
iii 
 
Abstract 
 The increasingly growing resistance to antibiotics has geared research efforts 
towards understanding the structure and function of antimicrobial peptides to gradually 
replace or reinforce the roles of antibiotics in therapeutic applications. Cathelicidins are a 
family of structurally diverse antimicrobial peptides that have only a single representative 
in humans, an antimicrobial peptide called LL37. LL37 is believed to play an important 
role in the first line of defense against local infection and systemic invasion of pathogens 
at sites of inflammation and wounds. LL37 kills bacteria by disrupting their membranes 
through non-specific peptide-lipid interactions, making it far more difficult for bacteria to 
develop resistance against than current antibacterial agents. Examining analogs of LL37 
could provide insight into its structure, function, and antimicrobial properties. Three of 
these variations were synthesized and purified: two truncated forms of LL37 (SK29 and 
FF33) as well as N-terminally extended LL37 (FALL39) for comparative studies. 
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1. Introduction 
1.1 Amino Acids, Peptides, and Proteins 
There are twenty amino acids that occur regularly in nature and make up the 
building blocks for peptides and proteins. All amino acids have a general formula 
illustrated in Figure 1.  
 
Figure 1: General structure of amino acids.1 
Amino acids possess an acidic carboxyl group and a basic amino group, in addition to a 
unique side chain bound to the same chiral carbon atom. All amino acids produced in 
vivo occur in the L-conformation with respect to the central chiral carbon atom. Amino 
acids are commonly classified based on the nature of their side chain (R-group). These 
classes include non-polar, polar, basic, and acidic amino acids. The twenty naturally 
occurring amino acids are shown in Figure 2, grouped into their respective classes. 
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Figure 2: The twenty naturally occurring amino acids.1 
Amino acids are commonly joined through a condensation reaction in which the 
carboxy-terminus of one amino acid reacts with the amino-terminus of another to form a 
peptide bond and water.  This reaction is illustrated below in Figure 3. 
 
Figure 3: Formation of the peptide bond.2 
When fifty amino acids or less are joined by peptide bonds, the molecule is typically 
called a peptide.  Once the chain lengthens past fifty residues, it is generally referred to as 
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a polypeptide. Proteins are formed when multiple polypeptides are joined together in a 
biologically functional way.  Slight modifications in the sequence of amino acids can 
result in drastic changes in the structure and function of proteins.  
1.2 Protein Structure 
Protein structure is classified into four distinct levels: primary, secondary, tertiary, 
and quaternary. The primary structure is simply the actual amino acid sequence that 
makes up a protein prior to any folding. As the chain of amino acids lengthens, some 
rotation occurs around the peptide bonds, and hydrogen bonding (H-bonds) typically 
results in the formation of a secondary structure. The hydrogen bonds may be within one 
chain or between different chains. This interaction of the amino acids leads to formation 
of either an α-helix, β-sheet, or random coil, which are synonymous with protein 
secondary structure. In the α-helix, hydrogen bonds are formed within the same chain, 
between amino acids four residues apart, as in the α-helix of hemoglobin. In β-sheets, 
hydrogen bonding links adjacent chains, or can be intrachain, but the backbone is more 
extended. Tertiary structure results from the interaction of multiple secondary structures 
as the protein folds and coils to attain a more compact three dimensional structure. These 
structures are held together by several different forces, including hydrogen bonds, 
disulfide bonds, van der Waals forces, and electrostatic and hydrophobic interactions. 
These different levels of protein structure are shown in Figure 4.  
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Figure 4: Primary, secondary, and tertiary protein structure.1 
The fourth level of protein structure is quaternary structure. Quaternary structure 
is composed of multiple tertiary structures formed into compact units called sub-units, 
which combine to form the overall protein.  Once proteins are fully formed, they typically 
have at least one location where they interact with a specific biochemical.  These 
locations are called active sites and are designed so that only certain molecules with 
distinct structures or characteristics can bind to them.3  Any changes to the protein’s 
structure in that region could inactivate the site, thus preventing binding and/or causing 
loss of function. 
1.3 Antimicrobial Peptides  
Antimicrobial peptides show a broad spectrum of antimicrobial activity and are 
found among all classes of life.4 These peptides seem to be representative of an ancient 
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defense strategy of eukaryotes against bacteria due to their high conservation and large 
diversity, which is observed even in closely related species.5 Since antimicrobial peptides 
are so widespread, they are thought to be conserved throughout evolution as part of the 
innate immune response. The increasingly growing resistance to antibiotics has geared 
research efforts towards understanding the mechanistic and potential roles of 
antimicrobial peptides with development for replacing or reinforcing the roles of 
antibiotics in therapeutic applications.6 In addition, antimicrobial peptides have also been 
reported to modulate various disease curbing processes in the body such as influencing 
inflammation, chemotaxis, the release of cytokines, and maintaining the balance of 
proteases and protease inhibitors.7 Thus, they also have a role as potential drugs in the 
treatment of wounds and inflammation.  
The exact mechanism by which antimicrobial peptides kill microorganisms has 
yet to be fully understood.  They are known to actively bind to microbial membranes, 
although the exact conformation they are in during binding is still being researched. 
Antimicrobial peptides tend to be rich in the positively charged amino acids: lysine, 
arginine, and histidine. This allows them to bind the typically negatively charged cell 
membranes of bacterial pathogens while leaving neutral charged eukaryotic membranes 
intact.8 Once bound to the membrane, they seem to make it permeable to ions and other 
cellular content, which causes great harm or even death to the cells.  There are currently 
three different models to explain how antimicrobial peptides permeate bacterial cell 
membranes, as shown in Figure 5.  
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Figure 5: An overview of AMP membrane permeability models.9 
Figure 5 (A) shows the antimicrobial peptides in solution not yet bound to the 
lipid bilayer bacterial membrane. The antimicrobial peptide is bound to the membrane as 
a cylindrical monomer in (B), and multiple peptides have self-assembled and bound to 
the membrane in (C). The three models of membrane permeability are shown in (D), (E), 
and (F).  In the first model, (D), the peptides form a pore across the membrane.  This is 
known as the “barrel-stave” model. The toroidal wormhole model shown in (E) appears 
very similar to (D), with a pore through the membrane, but closer examination shows 
negatively charged lipid head groups lining the pore that compensate for the positive 
charged peptides. The final model shown in (F) is known as the carpet model, where the 
membrane is simply disrupted by a high local concentration of peptides in a non-
structured manner. 
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1.4 The Human Cathelicidin, LL37 
 Cathelicidins are a family of structurally diverse antimicrobial peptides that are 
located at the carboxyl terminus of a 15-18 kDa highly conserved cathepsin-L-inhibitor 
(cathelin)-like domain.10 All cathelicidin family members are synthesized and stored in 
cells as two-domain proteins. These are split on demand to produce a cathelin protein and 
an antimicrobial peptide.11 Cathelicidins have only a single representative in humans, an 
antimicrobial peptide called LL37.  It derives its name from the first two residues at the 
N-terminus (Leucine, Leucine) and its length of amino acids (37). It is synthesized as an 
18 kDa propeptide (hCAP18) consisting of a 13.5 kDa N-terminal cathelin-like domain 
and the 4.5 kDa active peptide, LL37.10 A diagram of the structure of hCAP18 is shown 
in Figure 6. 
 
Figure 6: Diagram illustrating the structure of human cathelicidin – hCAP18.12 
 
The mature active peptide was originally isolated from degranulated 
granulocytes.5 LL37 showed moderate antibacterial activity in LB (Luria-Bertani) 
medium but a pronounced increase in antibacterial activity on E (a salt medium used for 
culturing E. coli) medium.13 Since LL37 still retains broad-spectrum activity in high salt 
medium, this represents typical physiological conditions and could be advantageous for 
potential therapeutic applications. LL37 is a positively charged molecule with the charge 
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being conferred by the high content of basic amino acids, arginine and lysine. At 
physiological pH, LL37 has 16 out of its 37 residues charged, including two aspartic acid 
and three glutamic acid residues carrying negative charge, and six lysine and five 
arginine residues bearing positive charge. The resultant net charge at physiological pH is 
therefore positive (+6). LL37 contains no cysteine residues and is thus absent of disulfide 
bridges.  This makes synthesizing it much easier and less expensive.  The exact sequence 
is shown below in Figure 7. 
LLGDF–FRKSK–EKIGK–EFKRI–VQRIK–DFLRN–LVPRT-ES 
Figure 7: Primary structure of LL37 
The secondary structure of LL37 is typically an α-helix, with its specific structure being 
anion-, pH-, and concentration dependent.13 It adopts an α-helix structure in hydrophilic 
environments and a coiled structure in hydrophobic environments.14 The amphipathic 
nature of LL37 enables it to bind bacteria with both hydrophobic and electrostatic 
interactions. Figure 8 shows an electrostatic surface plot of LL37 in an assumed perfect 
α-helical conformation. You can clearly see the hydrophilic surface on the top (blue) and 
a hydrophobic surface on the bottom (white), which is a common feature of all 
antimicrobial peptides. In the bottom part of Figure 8 is a cartoon representation showing 
that the N-terminal region of LL37 shows a lack of amphipathic topology.  Instead, this 
region consists of stretches of hydrophilic and hydrophobic residues that may be 
responsible for the complex signaling functions of LL37, rather than its antimicrobial 
properties.11 
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Figure 8: Hypothetical amphipathic α-helix structure of LL37.11  
 
Upon accumulation of a threshold concentration of LL37 on bacterial cell 
membranes, the membrane is altered through an unknown mechanism, resulting in the 
formation of ion channels. These aqueous pores typically lead to cell death via 
hypoosmotic lysis. The entry of the peptide into the cell membrane also leads to leakage 
of the cell cytoplasm and its contents into the extracellular space. The electron 
micrographs in Figure 9 show how a bacterium is affected by LL37. The bacterium dies 
if a threshold called “minimum inhibitory concentration” (MIC) is reached.15 Substantial 
damage to the cell is still observed, even if LL37 is present at a lower concentration than 
the MIC.  
 
N-terminal 
C-terminal 
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Figure 9: A series of electron micrographs of LL37 affected bacterium.15 
In vivo, LL37 is bound by plasma proteins, thereby inhibiting its activity toward 
human cell membranes. Studies have demonstrated that truncating the peptide further 
reduces its cytotoxic activity towards eukaryotic cells, making it amenable as a possible 
therapeutic drug.16 Research efforts are therefore geared towards developing truncated 
LL37 peptides that selectively kill microbes and avoid inflicting any damage to human 
cells.  
LL37 is encoded by a gene located on chromosome three in humans and is 
expressed in the squamous epithelium of airways, mouth, and intestines.17 This peptide is 
constitutively expressed in the spleen, liver, stomach, and intestines. In addition, various 
body secretions such as semen, wound fluid, saliva, and sweat contain LL37.18 
Studies by Oren et al. have identified LL37 as having several properties setting it 
apart from other antimicrobial peptides.16 Most native antimicrobial peptides are highly 
susceptible to enzymatic degradation in solution, unlike LL37, which oligomerizes in 
solution, thus protecting it from proteolytic degradation. The fact that LL37 is able to 
11 
 
oligomerize in solution is especially surprising given the fact that it is positively charged.  
Given that the N-terminal of LL37 is hydrophobic and contains 30% of the hydrophobic 
residues in the peptide, they may serve as a hydrophobic core of the oligomer.  LL37 also 
has five negatively charged residues spread throughout the chain, which may form salt 
bridges with the positively charged residues, thus stabilizing the oligomer. The peptide 
also resists degradation when bound to both zwitterionic (mimicking mammalian 
membranes) and negatively charged membranes (mimicking bacterial membranes). Most 
other antimicrobial peptides are protected from degradation only when bound to 
negatively charged membranes. LL37 is also able to bind and permeate both zwitterionic 
membranes and negatively charged membranes, while other native antimicrobial peptides 
only permeate negatively charged membranes efficiently. Last, LL37 is self-associated 
when bound to zwitterionic phospholipid vesicles but dissociates into monomers upon 
binding negatively charged vesicles.  Antimicrobial peptides typically are monomeric 
when bound to zwitterionic and negatively charged membranes.  
Aside from its important antimicrobial properties, LL37 also has been reported to 
serve other roles such as a chemo-attractant of mast cells, neutrophils, monocytes, NK 
cells, and T-cells to the sites of infection. This is achieved through interactions with the 
formyl peptide receptor like-1 that also promotes angiogenesis.19,20 Also, elevated levels 
of LL37 are seen in areas of inflammation, such as an infected tissue.21 LL37 induces 
mast cells to degranulate and releases pro-inflammatory mediators such as histamines, 
which promote infiltration of inflammatory cells.22 LL37/hCAP18 was found to bind 
lipopolysaccharide, inhibit its multiple biological activities in vitro, and reduce its 
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lethality in murine models of endotoxaemia.23 LL37 has been associated with tissue 
repair and wound healing.24  
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2. Research Goals and Objectives 
 This project involves the synthesis, purification, and analysis of three peptides 
based on LL37, a human cathelin-associated antimicrobial peptide.  LL37 is believed to 
play an important role in the first line of defense against local infection and systemic 
invasion of pathogens at sites of inflammation and wounds.16 Understanding its mode of 
action may assist in the development of new antimicrobial agents that mimic the human 
immune system rather than conventional antibiotics.  
The emergence of antibiotic-resistant strains of several different bacteria has 
necessitated the development of new ways to fight resistant bacterial infections. LL37 
kills bacteria by disrupting their membranes through non-specific peptide-lipid 
interactions, making it more difficult for bacteria to develop resistance against than some 
current antibacterial agents.  Although the general mechanism of action is known 
(permeabilization of the cell membrane), the exact mechanism is still under debate. 
LL37’s specific membrane selectivity targets bacteria while leaving other cells intact.  
Additionally, LL37 has been shown to have roles in wound healing, attraction of white 
blood cells, and inflammation regulation.  LL37 has been examined extensively, and 
several variations of its sequence have also been studied due to its possible 
pharmaceutical properties.  Examining its analogs could provide more potent potential 
drugs or information on its function.  My goal was to synthesize three of these variations, 
two truncated forms of LL37 (SK29 and FF33) and an N-terminally extended LL37 
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(FALL39) for comparative studies.  The amino acid sequences of these peptides are 
shown in Figure 10. 
                   1             5              10              15             20             25              30              35         
LL37  L L G D F F R K S K E K I G K E F K R I V Q R I K D F L R N L V P R T E S 
FF33  F F R K S K E K I G K E F K R I V Q R I K D F L R N L V P R T E S 
SK29  S K E K I G K E F K R I V Q R I K D F L R N L V P R T E S 
FALL39  F A L L G D F F R K S K E K I G K E F K R I V Q R I K D F L R N L V P R T E S 
Figure 10:  Amino acid sequences of proposed antimicrobial peptides. 
  
These peptides were prepared using standard Fmoc solid phase peptide synthesis 
on a Symphony automated peptide synthesizer from Protein Technologies, Inc. and 
purified by reverse phase HPLC.  Major challenges included modification of the 
synthesis in the event that the correct peptide could not be isolated and obtained with a 
final purity >90%. 
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3. Peptide Synthesis: A Brief History 
The current most common method of peptide synthesis uses solid phase 
techniques initially developed by R. B. Merrifield and published in the Journal of the 
American Chemical Society in 1963.25 Merrifield used a chloromethylated polystyrene 
polymer as a support for repeated step-wise carbodiimide coupling reactions, which 
lengthened the peptide from its amino-end. His initial synthesis yielded a four-amino acid 
sequence with many by-products from incomplete coupling reactions, but his idea would 
eventually become the industry standard that is still the preferred method today.   
Merrifield’s solid phase technique for peptide synthesis ignored some of the basic 
principles of organic synthesis at the time. His method did not isolate and characterize the 
product at each step, instead waiting until the completion of the synthesis to cleave the 
peptide from the solid support and purify it to the desired level. This resulted in a method 
that was fast, simple, and efficient. He later improved upon his original conditions 
through the use of N-terminal t-butoxycarbonyl protecting groups and benzyl derivatives 
for side chain and carboxy terminal protection. He was able to synthesize and purify the 
nonapeptide sequence of bradykinin in a mere nine days, with an astounding yield for the 
time at 68%.26   
Although his method was certainly groundbreaking, it was not without faults.  
The temporary N-terminal protecting groups, the more permanent side chain protecting 
groups, and the peptide-resin linkage were all acid labile. This meant that some of the 
side chain protecting groups would be removed at each step and resulted in undesired 
16 
 
products at the conclusion of the synthesis. In addition, small amounts of the peptide 
would be cleaved from the resin and washed away at each step, lowering the overall 
yield. These effects were compounded throughout the synthesis, making the possibility of 
synthesizing longer peptides quite difficult. In addition, the technique required the use of 
strong acids that are very hazardous and dangerous to handle.  Trifluoroacetic acid (TFA) 
was typically used for the N-terminal deprotections, and hydrogen fluoride (HF) was 
used for the peptide cleavage and removal of side chain protecting groups. 
In 1972, Carpino suggested the use of a base labile N-terminal protecting group, 
9-fluorenylmethoxycarbonyl (Fmoc).27 Although its adoption was initially slow, Fmoc 
solid phase peptide synthesis quickly took off with the arrival of commercially available 
Fmoc-amino acids. Now the resin-bound peptide could be deprotected prior to each 
coupling using a 20% solution of piperidine in dimethyl formamide (DMF). The acid 
labile peptide-resin linkage as well as the amino acid side chain protecting groups would 
remain intact as the chain was lengthened.28,29 Once the chain was completed, TFA could 
be used to cleave the peptide from the resin and remove the amino acid side chain 
protecting groups, thus avoiding HF altogether. The general scheme of solid phase 
peptide synthesis is shown below in Figure 11. 
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Figure 11: The general scheme of SPPS.30 
Another advantage was that fluorine derivatives have strong ultraviolet absorption 
that could be monitored for the completion of each deprotection step.31 This led to the 
development of fully automated peptide synthesizers, which could monitor the 
progression of the synthesis from one step to the next and even make decisions based on 
the ultraviolet absorption data. Although Fmoc solid phase peptide synthesis is now the 
preferred method, many complex reactions are still performed using the original Boc 
chemistry. The original Boc method is performed when unnatural amino acids or other 
derivatives that are base sensitive are incorporated into the sequence. 
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4. Synthesis and Analysis of Peptides 
4.1 Fmoc Solid Phase Peptide Synthesis 
 The first step in solid-phase peptide synthesis is to determine which resin to build 
the peptide on. Resin selection greatly affects the outcome of the synthesis, and there are 
many options commercially available.32 With relatively long, difficult sequences being 
synthesized, there is a need to consider the swelling properties of the resin as well as its 
ability to deter aggregation. Typically, SPPS is carried out on cross-linked polystyrene, 
and excellent results have previously been obtained using polystyrene (PS) resins that 
employed polyethylene glycol linkers (PEG-PS). PEG-PS resins are typically quite 
expensive. A literature search showed that a cheaper alternative was developed by 
Peptides International: Cross-Linked Ethoxylate Acrylate (CLEAR) resins. These resins 
offer the benefits of polyethylene glycol linkers for disruption of aggregation and also 
have better swelling properties than polystyrene resins in a wider variety of solvents.33 In 
addition, they were available with the first residue of all the proposed sequences, serine, 
preloaded. Ultimately, the shortest sequence of the LL37 related peptides, SK29, was 
attempted on the Fmoc-Ser(tBu)-CLEAR-Acid Resin (Product Code CFS-1243-PI), and 
the resin selection for the remaining, longer peptides was based on the analytical results 
of the SK29 synthesis.        
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4.2 Synthesis of SK29 
 100 µmol of Fmoc-Ser(tBu)-CLEAR-Acid Resin was weighed to a disposable 
fritted reaction vessel and placed on the Symphony peptide synthesizer. Each amino acid 
reservoir was filled with a 100 mM concentration of amino acid in DMF. For a 100 µmol 
synthesis, this will represent a 2.5x molar excess with a 2 volume (2.5 ml) delivery.  
Some of the amino acids require side chain protecting groups, and the ones used are listed 
below in Figure 12. 
Fmoc-Asp(OtBu)-OH 
Fmoc-Asn(Trt)-OH 
Fmoc-Gln(Trt)-OH 
Fmoc-Glu(OtBu)-OH 
Fmoc-Lys(Boc)-OH 
Fmoc-Ser(tBu)-OH 
Fmoc-Thr(tBu)-OH 
Fmoc-Arg(Pbf)-OH 
Figure 12: Amino acid side chain protecting groups. 
 
In addition to the 20 pressurized amino acid reservoirs on the front of the instrument, the 
Symphony has 6 available pressurized solvent bottles in the lower cabinet. Their contents 
are shown in Figure 13.  
 
Solvent 1 bottle: DMF solvent (wash) 
Solvent 2 bottle: 20% piperidine in DMF (deprotect) 
Solvent 3 bottle: 100 mM O-Benzotriazole-N,N,N’,N’-tetramethyl-uronium-hexafluoro-
phosphate (HBTU) and N-Hydroxybenzotriazole (HOBt)/400 mM N-Methylmorpholine 
(NMM) in DMF 
Solvent 4 bottle: empty 
Solvent 5 bottle: Dichloromethane (DCM) 
Solvent 6 bottle: Cleavage cocktail (Reagent B) 
Figure 13: Symphony reagent list. 
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The Symphony works by following a series of programs detailing what to deliver 
to the reaction vessel and also various other functions such as mixing and draining.  All 
of the bottles on the instrument are pressurized with nitrogen, and the reaction vessel is 
mixed by bubbling nitrogen from the bottom inlet of the reaction vessel. Solvents are 
drained from the bottom inlet of the reaction vessel by vacuum. The program for the first 
amino acid added is slightly different from the remaining residues to be coupled because 
the resin requires swelling and there is only a single coupling. Table 1 shows the program 
used for the coupling of the first amino acid residue. 
Step Solvent Bottle Volumes 
Mix 
Time Drain Rep Comments 
1 1 2 00:30 ON 1 Resin wash 
2 1 2 15:00 ON 1 Resin swelling 
3 1 2 00:30 ON 2 Resin wash 
4 2 2 10:00 ON 1 1x 10 min. deprotection 
5 1 2 00:30 ON 3 3x wash with DMF 
6 AA 2 00:00 OFF 1 Addition of amino acid 
7 3 2 45:00 ON 1 1x 45 min. coupling 
8 1 2 00:30 ON 3 3x wash with DMF 
 
Table 1: The program for the coupling of the first residue. 
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Once the first amino acid residue was coupled, the remaining residues were all added by 
double coupling, using the program provided in Table 2. 
Step Solvent Bottle Volumes 
Mix 
Time Drain Rep Comments 
1 1 2 00:30 ON 3 3x wash with DMF 
2 2 2 05:00 ON 1 1x 5 min. deprotection 
3 2 2 10:00 ON 1 1x 10 min. deprotection 
4 1 2 00:30 ON 6 6x wash with DMF 
5 AA 2 00:00 OFF 1 Addition of amino acid 
6 3 2 45:00 ON 1 1x 45 min. coupling 
7 AA 2 00:00 OFF 1 Addition of amino acid 
8 3 2 30:00 ON 1 1x 30 min. coupling 
9 1 2 00:30 ON 3 3x wash with DMF 
 
Table 2: Standard program for double coupling. 
 
4.3 Peptide Cleavage 
 The Protein Technologies Symphony peptide synthesizer allows for automated 
cleavage of the peptide from the resin. Once the cleavage is completed, the instrument 
delivers the product from the reaction vessel to a 10 mL centrifuge tube in a vented 
compartment. There is a separate pressurized bottle for the cleavage cocktail of your 
choice. For the cleavage of the LL37 related peptides, fresh Reagent B was prepared.  
Reagent B consists of 88% TFA/5% phenol/5% water/2% triisopropylsilane.34 Reagent B 
can result in the alkylation of unprotected tryptophan residues, but since none of the 
sequences contain tryptophan, this was not an issue.  
Following the synthesis, each peptide was bound to the resin within the reaction 
vessel, with N-terminal Fmoc protection still intact. The resin was then deprotected once 
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for five minutes followed by a second, ten-minute deprotection.  It was then washed six 
times with DMF, followed by three washes of DCM. It was then dried with a stream of 
nitrogen for 30 minutes. At this point, 5 mL of reagent B was delivered to the reaction 
vessels and allowed to mix using nitrogen bubbling for two hours.  The cleavage cocktail 
was then transferred to the collection tube. An additional 2.5 mL of reagent B was 
delivered to the reaction vessel and bubbled with nitrogen for five minutes as a wash step. 
This additional cleavage cocktail was then also transferred to the collection tube. The 
collection tube was then removed from the Symphony and added dropwise to 40 mL of 
cold (-20°C) methyl tert-butyl ether (MTBE) in a 50 mL centrifuge tube. The 10 mL 
cleavage collection tube was then rinsed with excess cold MTBE and transferred to the 
50 mL centrifuge tube. The ether solution was then stored overnight in a freezer (-20°C). 
The following day, the ether solution was centrifuged, resulting in the precipitated 
peptide collecting in the bottom of the 50 mL centrifuge tube. The ether solution was 
poured off, and fresh cold ether was added to remove any residual scavengers. The pellet 
was disrupted by vigorous shaking, and the ether solution was centrifuged again. This 
process was repeated for a total of three washes. After the final wash, the ether was 
poured off, and the peptide precipitate was allowed to dry in a hood for two hours. The 
peptides were then dissolved in 25 mL of 50% acetonitrile (ACN)/50% water and frozen 
in liquid nitrogen for overnight lyophilization. Following lyophilization, the crude 
material yielded 200 mg of fluffy white powdered peptide.   
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4.4 Analysis and Purification Methods 
 All three LL37 related peptides were HPLC purified with the goal of achieving at 
least 90% purity. The instrumental system information for both the analytical and 
preparative HPLC is presented in Table 3. Both HPLC systems utilized a two-solvent 
gradient, with solvent A being composed of 99.9% water with 0.1% TFA and solvent B 
composed of 80% ACN, 19.9% water, and 0.1% TFA.  
Analytical 
HPLC 
Beckman System Gold HPLC 
32-Karat software ver. 5.0 
Model 125 solvent delivery module 
Model 166 UV-VIS Detector 
Model 508 Autosampler 
Analytical 
Column 
Macherey-Nagel Nucleosil 100-5 C18 
5µm particle size 
4.6 x 250 mm 
100 Å pore size 
Preparative 
HPLC 
Beckman System Gold HPLC 
32-Karat software ver. 5.0 
Model 125 solvent delivery module 
Model 166 UV-VIS Detector 
Beckman SC 100 Fraction Collector 
Preparative 
Column 
Macherey-Nagel Nucleosil 100-5 C18 
5µm particle size 
21 x 250 mm 
100 Å pore size 
 
Table 3: Liquid chromatography system information. 
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In addition, the peptides were verified to have the correct mass by mass 
spectrometry. Mass spectrometry was performed using a Thermo Finnigan LCQ Duo 
mass spectrometer with an electrospray source and Xcaliber software.   
4.5 Analysis and Purification of SK29 
Initially, the crude product of SK29 was analyzed by mass spectrometry to verify 
that it had the correct average molecular weight of 3516.15 amu. The sample was 
dissolved in 50% acetonitrile/50% water with 1% formic acid to promote protonation. 
The spectrum is shown below in Figure 14.  
 
Figure 14: Mass spectrum of crude SK29. 
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SK29, Crude, MW=3516.15 
[M+3H]+3 = 1172.6 
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[M+6H]+6 = 587.1 
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The mass spectrum shows the mass to charge ratio (m/z) from 150 to 2000 of all 
the ionized molecules present in the sample. The most abundant ion in the spectrum is 
seen at a mass to charge ratio of 704.1. This corresponds to SK29 ionized to +5 (MW = 
3516.15 + 5H+ = 3521.15). The mass to charge ratio is thus 3521.15/5 = 704.2. Four 
other relatively abundant ions attributed to SK29 are seen and listed in Figure 14. 
Following confirmation that the crude peptide had the correct molecular weight, it 
was analyzed by HPLC to determine the crude purity and identify a possible gradient to 
use for its purification. A sample of the peptide was dissolved in 0.1% TFA in water and 
analyzed using a gradient of 25-85% solvent B in 25 minutes. The flow rate was set to 
1.0 mL/min. and the detector monitored at the absorbance of the peptide bond at a 
wavelength of 215 nm.35 The peptide was found to be 45% pure by the percent area of the 
main peak at retention time (RT)=17.433 minutes, as seen in Figure 15. 
 
Figure 15: Crude HPLC chromatogram of SK29. 
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For the actual HPLC purification of SK29, the sample was dissolved in 20 mL of 20% 
ACN/80% water. Since the preparative HPLC had a sample loop of 5 mL, complete 
purification of the sample took four runs, with approximately 50 mg being purified in 
each run. The gradient for the analysis was 25-85% solvent B in 60 minutes with a flow 
rate of 5.0 mL/min. The detector monitored the absorbance at 215 nm. Fractions were 
collected every 30 seconds for the entire 60-minute run. A representative chromatogram 
of one of the four runs is shown below in Figure 16. 
 
Figure 16. Preparative HPLC chromatogram of SK29. 
 
Following each preparative run, fraction tubes were selected and run on the 
analytical HPLC to determine whether the desired 90% purity level was achieved. Once 
all the pure tubes were determined, they were combined and lyophilized overnight. The 
final product was analyzed by mass spectrometry and analytical HPLC to provide the 
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final results, which are shown below in Figures 17 and 18. The final peptide was 98.93% 
pure with a yield of 56 mg. 
 
Figure 17: Mass spectrum of purified SK29. 
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Figure 18: Final HPLC chromatogram of purified SK29. 
 
4.6 Synthesis and Purification of FF33  
 The synthesis of FF33 was set up in the exact same manner as SK29, except with 
the addition of four amino acids at the N-terminus.  Following lyophilization of the crude 
peptide, the yield was 206 mg. When the crude product was analyzed by mass 
spectrometry, the expected molecular weight was not found. The ionization pattern 
resembled the spectrum of SK29 (Figure 14) and is shown in Figure 19. 
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Figure 19: Mass spectrum of crude FF33. 
Although the peptide could have been sequenced in order to confirm the 
incomplete coupling of the final four residues, the mass spectrum was conclusive enough. 
The poor coupling was most likely due to some aggregation or formation of secondary 
structure as the synthetic chain was lengthened past 29 residues. In fact, it has been 
shown that aggregation can occur beginning with the fifth residue coupled.36 Since the 
synthesis and purification of SK29 were successful, the coupling of the final four residues 
of FF33 appeared to be problematic. Each residue was already double coupled for an 
extended time period, so extending the coupling times or adding additional couplings was 
ruled out. The peptide had already been cleaved from the resin, so the synthesis would 
have to be started over from scratch, and making modifications to the second synthesis 
seemed to offer the best opportunity for success. 
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 The insertion of a proline or N-alkyl amino acid into the peptide sequence has 
been shown to reduce the formation of secondary structures and diminish aggregation.37  
Unfortunately, the sequence could not be modified, but two approaches that exploit this 
principle while still maintaining the desired sequence were found. The first method 
involves the use of 2-hydroxy-4-methoxybenzyl (Hmb) protecting groups.38,39 
Incorporating Hmb protected amino acids typically postpones the onset of aggregation 
for as many as six residues, and the Hmb group is effectively removed by standard 
cleavage procedures.40,41  There are also several Hmb protected amino acids available 
commercially for Fmoc SPPS; however, they are very expensive.   
 The second method to disrupt secondary structure formation and reduce 
aggregation is the use of pseudoproline dipeptides in the sequence. This method, 
developed by Mutter, involves converting a serine, threonine, or cysteine residue into an 
oxazolidine dipeptide, with the serine, threonine, or cysteine on the C-terminus.42 Many 
different configurations are commercially available with the added benefit of adding two 
residues in one coupling reaction. The oxazolidine is also removed by TFA, allowing for 
cleavage of the peptide using typical reagents.43 The pseudoproline residues are less 
expensive but more restrictive than Hmb protected amino acids because they require 
either a serine, threonine, or cysteine in the sequence. Since the N-terminal amino acid of 
SK29 is a serine and the next residue in FF33 is a lysine, it was ultimately decided to 
incorporate Fmoc-Lys(Boc)-Ser(psiMe,Mepro)-OH from EMD Biosciences into FF33 
and determine if that would enable the completion of the synthesis.  
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 A second synthesis of FF33 was performed (FF33B), using the exact same 
conditions as the first synthesis, but substituting Fmoc-Lys(Boc)-Ser(psiMe,Mepro)-OH 
into the sequence prior to the last three amino acids being coupled. The pseudoproline 
dipeptide simply replaced the Lys-Ser in the sequence and was added with the same 
double coupling program as the other amino acids. Following lyophilization of the crude 
peptide, the yield was 230 mg. Analysis of the crude product by mass spectrometry 
identified the expected molecular weight of FF33, in addition to a byproduct of 
incomplete cleavage as shown in Figure 20. 
 
Figure 20: Mass spectrum of crude FF33B. 
The crude peptide was then analyzed by HPLC to determine the purity and to help 
develop a method for purification. A sample of the peptide was dissolved in 0.1% TFA in 
water and analyzed using a gradient of 25-85% solvent B in 25 minutes. The flow rate 
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was set to 1.0 mL/min. and the detector monitored absorbance at 215 nm. The peptide 
was 60% pure by percent area of the main peak at RT=17.392 minutes. The 
chromatogram is illustrated in Figure 21. 
 
Figure 21: Crude HPLC chromatogram of FF33B. 
In order to ensure that the main peak was actually the desired peptide, the peak was 
collected and the solution was analyzed by mass spectrometry. The spectrum is shown 
below in Figure 22.  Five mass to charge ratios attributable to FF33 are identified in the 
spectrum, and it is almost completely devoid of impurities. 
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Figure 22: Mass spectrum of peak at RT=17.392 minutes in crude FF33B. 
FF33B was then dissolved in 25 mL of 25% ACN/75% water and injected over 
the course of five runs on the same system as the SK29 purification. This accounted for 
approximately 45 mg per purification. A representative chromatogram of one of the five 
runs is shown in Figure 23.   
 
Figure 23: Preparative HPLC chromatogram of FF33B. 
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Following each preparative run, fraction tubes were selected and run on the 
analytical HPLC to determine whether the desired 90% purity level was achieved. Once 
all the pure tubes were determined, they were combined and lyophilized overnight. The 
final product was then analyzed by mass spectrometry and analytical HPLC to provide 
the final results, which can be seen below in Figures 24 and 25. The final peptide was 
98.67% pure with a yield of 57 mg. 
 
Figure 24: Mass spectrum of purified FF33B. 
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Figure 25: Final HPLC chromatogram of purified FF33B. 
 
4.7 Synthesis and Purification of FALL39  
 Following the successful synthesis of FF33B, it seemed feasible that FALL39 
could be successfully synthesized in a similar manner. The synthesis was set up in the 
exact same manner as FF33B, except with the addition of six amino acids at the N-
terminus. Once again, the Lys-Ser pseudoproline residue was incorporated into the 
peptide, but there was still some concern about aggregation due to the additional residues 
at the N-terminus. Following lyophilization of the crude peptide, the yield was only 170 
mg. Despite the lower yield, the crude peptide showed the correct mass, and the spectrum 
is shown in Figure 26.  
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Figure 26: Mass spectrum of crude FALL39. 
A small sample of the peptide was dissolved in 0.1% TFA and injected to 
determine its crude purity, which was only 40.38% by percent area of the main peak seen 
at RT=20.167 minutes. The chromatogram is shown below in Figure 27. 
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Figure 27: Crude HPLC chromatogram of FALL39. 
FALL39 was then dissolved in 15 mL of 25% ACN/75% water and injected over 
the course of three runs on the same system as SK29 and FF33B. This accounted for 
approximately 55 mg per purification. A representative chromatogram of one of the three 
runs is shown below in Figure 28.   
 
Figure 28: Preparative HPLC chromatogram of FALL39. 
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Following each preparative run, fraction tubes were selected and run on the 
analytical HPLC to determine whether the desired 90% purity level was achieved. Once 
all the pure tubes were determined, they were combined and lyophilized overnight. The 
final product was then analyzed by mass spectrometry and analytical HPLC to provide 
the final results, which can be seen below in Figures 29 and 30. The final peptide was 
99.26% pure, as seen by the predominantly single HPLC peak and less complex mass 
spectrum, with a yield of 46 mg. 
 
 
Figure 29: Mass spectrum of purified FALL39. 
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Figure 30: Final HPLC chromatogram of purified FALL39. 
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5. Future Work 
 With the successful synthesis of all three desired LL37 related peptides, work can 
begin on determining the structural and molecular principles for their antimicrobial 
action. It is well characterized that antimicrobial peptides kill bacteria by membrane 
disruption, but the exact mechanism of disruption has yet to be determined.44 Once it is 
fully understood how these peptides are able to disrupt bacterial membranes, the 
development of new synthetic agents that could alleviate our current issues with 
antibiotic resistance may be possible.   
 The first objective will be the determination of secondary structure of the three 
LL37 related peptides using circular dichroism (CD) spectroscopy. Analyzing the 
structure of the peptides in water solution as well as a lipid environment will allow the 
determination of whether the structures vary across different conditions, such as pH, 
temperature, and buffer. The results of these experiments will hopefully allow 
optimization of the conditions for high-resolution structural studies by nuclear magnetic 
resonance (NMR) spectroscopy. 
 Since it has been shown that N-terminal truncation of LL37 to SK29 causes a loss 
of antibacterial activity, it is necessary to identify the reason for this loss of function and 
also to determine if the less truncated FF33 peptide still retains function.13 In addition, the 
function of FALL39 needs to be compared with that of LL37 in order to determine the 
effects of additional N-terminal residues. This can be achieved through an examination of 
the high-resolution structure of LL37 and all three related peptides in solution and in 
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micelles using solid-state NMR methods. This will be followed by a study of the 
structure, dynamics, and topology of LL37 and all three related peptides in phospholipid 
bilayers using solid-state NMR.  An investigation into the antimicrobial peptide-
membrane interaction and the mechanism of membrane disruption using solid-state NMR 
and differential scanning calorimetry (DSC) will also be necessary.     
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